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Abstract
Background: In this population-based study, we investigated the degree of concordance between Gleason scores
obtained from prostate biopsies and those obtained from prostatectomy specimens, as well as the determinants of
biopsy understaging.
Methods: We considered for this study all 371 prostate cancer patients recorded at the Geneva Cancer Registry
diagnosed from 2004 to 2006 who underwent a radical prostatectomy. We used the kappa statistic to evaluate the
Gleason score concordance from biopsy and prostatectomy specimens. Logistic regression was used to determine
the parameters that predict the undergrading of the Gleason score in prostate biopsies.
Results: The kappa statistic between biopsy and prostatectomy Gleason score was 0.42 (p < 0.0001), with 67%
of patients exactly matched, and 26% (n = 95) patients with Gleason score underestimated by the biopsy. In a
multi-adjusted model, increasing age, advanced clinical stage, having less than ten biopsy cores, and longer delay
between the two procedures, were all independently associated with biopsy undergrading. In particular, the
proportion of exact match increased to 72% when the patients had ten or more needle biopsy cores. The main
limitation of the study is that both biopsy and prostatectomy specimens were examined by different laboratories.
Conclusions: The data show that concordance between biopsy and prostatectomy Gleason scores lies within the
classic clinical standards in this population-based study. The number of biopsy cores appears to strongly impact on
the concordance between biopsy and radical prostatectomy Gleason score.
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Background
The Gleason grading system, based upon architectural
features of prostate cancer cells, is the most widely used
histological grading method for prostatic adenocar-
cinoma. The Gleason score (GS) closely correlates with
clinical behavior, and provides an important index of
prognosis. Furthermore, this score is one of the key de-
terminants in treatment decision making, together with
stage, age and prostate-specific antigen [1]. Indeed, most
models who were developed to predict the likelihood of
pre-treatment findings with long-term outcomes, incor-
porate biopsy GS [1].
Significant discrepancies exist between the GS deter-
mined by the prostate biopsy, and the GS based upon
the pathologic specimen. It has been observed that the
GS from needle biopsies underestimates the GS of the
radical prostatectomy specimen in 19 to 57% of all cases
depending on the series and the periods examined [2-8].
Such downgrading has a significant impact on treatment
decisions and patient outcomes, particularly when the
choice of treatment is between active surveillance and
curative intent therapy.
Several factors can influence the likelihood that the bi-
opsy GS underestimates the prostatectomy score, inclu-
ding the PSA level, the level of pathologist expertise, the
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patient’s age, the results of the digital rectal examination,
the prostate gland volume, the percentage of cancer cells
in the biopsy sample and the number of biopsies
obtained [5,7,9-11]. With reference to the last issue, it
is worth mentioning that the European Association of
Urologists (EAU) in 2008 recommended obtaining at
least 10 cores during the biopsy [12], while in the most
recent guidelines reduced this number to eight [13].
In this population-based study, we investigated the de-
gree of concordance between GSs obtained from needle
biopsy of the prostate and radical prostatectomy, and we
assessed the parameters that may be related to un-
dergrading the GS in prostate biopsy.
Methods
Using data from the population-based Geneva Cancer
Registry, we considered for this study all 371 prostate
cancer patients diagnosed from 2004 to 2006, who
underwent a radical prostatectomy.
The Geneva Cancer Registry collects information from
various sources and is considered accurate, as witnessed
by its very low percentage (<2%) of cases recorded from
death certificates only [14]. All hospitals, pathology la-
boratories, and private practitioners in the canton of
Geneva are requested to report every cancer case.
Trained tumor registrars systematically extract data from
medical and laboratory records and physicians regularly
receive enquiry forms to complete missing data.
Recorded data for each cancer case include sociodemo-
graphic variables; method of detection; prostate-specific
antigen (PSA) value at diagnosis; tumor characteristics
(including histology, differentiation based on tumor grade,
and GS); stage at diagnosis according to both clinical and
pathological TNM classification; lymph node status; treat-
ment; survival status; and cause of death. Different la-
boratories, from both the public and the private sector,
examine biopsy and prostatectomy specimens in Geneva.
For this study, the variables of interest were age, socioeco-
nomic status based on the patient’s last occupation (high,
middle, low, unknown), sector of care of the first treat-
ment (public, private), PSA value at diagnosis (<10 ng/ml,
10–20, >20) and clinical stage (T1-T2, T3-T4, Tx). For
each patient, we retrieved information on the number of
biopsy cores and the volume of the prostate in cubic centi-
meters (cm3). We also calculated the number of biopsy
procedures performed by each operator during the study
period within the study population as an indicator of the
experience of the biopsy performers. To account for the
possibility of a change in the severity of the disease occur-
ring during the delay between the biopsy and the prosta-
tectomy, we calculated the difference in days between the
prostatectomy and the biopsy dates.
Concordance between biopsy and prostatectomy GSs
was calculated through the kappa statistic [15]. The kappa
statistic corrects for agreement expected by chance: kappa
values < 0 indicates poor agreement; 0 to < 0.20 indicate
slight agreement; 0.21 to < 0.40 indicate fair agreement;
0.41 to < 0.60 indicate moderate agreement; 0.61 to < 0.80
indicate substantial agreement; and 0.81 to ≤ 1.0 indicate
almost perfect agreement [16]. We calculated kappa for
the individual GS (2 to 10) and for categories of GS (≤6, 7,
8–10). Rates of undergrading of GS categories were
calculated and with logistic regression we assessed deter-
minants of GS categories undergrading. We used a case–
control approach considering as cases those patients
whose biopsy GS was lower than the prostatectomy GS,
and as controls everybody else. In the multivariate analysis
we used the back step procedure, entering all the variables
statistically significant in univariate analysis at the same
time.
All data analysis was conducted at the Geneva Cancer
registry. The Registry has general registry approval by
the Swiss Federal Commission of Experts for professional
secrecy in medical research (Commission d’experts pour
le secret professionnel en matière de recherche medical).
This approval permits cancer data collection and its use
for research purposes.
Results
The prostate cancer patients were on average 63 (±6.3)
years old at diagnosis. For 242 (65%) patients, the PSA
value at diagnosis was below 10 ng/ml; the clinical stage
was classified as T1-T2a for 73% of patients. The median
prostate volume was 36.6 cc (range 4–166) and the me-
dian number of biopsy cores was 10 (range 2–22). Thirty
percent of patients had a biopsy by a physician per-
forming less than 10 biopsies in the three-year study
period. The median delay between biopsy and prostatec-
tomy was 84 days (range 7–412).
Figure 1 shows the concordance between biopsy and
prostatectomy individual GSs. An exact match was obser-
ved for 67% of patients (n = 248) while for 26% (n = 95)
the GS was underestimated by the biopsy; in 7% of pa-
tients, it was overestimated. The kappa statistic was 0.42,
indicating a moderate agreement. When considering the
categories of GS (≤6, 7, 8–10) the patients understaged by
the biopsy were 87 (23%) while the GS matched for 267
patients (72%). The kappa for the categories of GS was
0.48 (p < 0.0001), also indicating a moderate agreement.
Over 30% of patients classified as Gleason score six or less
from the biopsy, were Gleason score seven or more
according to the prostatectomy.
The concordance significantly differed across catego-
ries of needle cores, number of biopsies performed by
the operator and time between the biopsy and the pros-
tatectomy. The kappa statistic for the patients who had
nine or less biopsy cores was 0.35 (p < 0.001) and the
proportion of concordance was 62%. For the patients
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who had 10 or more biopsy cores the kappa statistic was
0.49 (p < 0.001) and the proportion of concordance in-
creased to 72%. The kappa statistic between biopsy and
prostatectomy GS was 0.34 (p < 0.001) for the patients
who had their biopsy performed by an operator with less
than 30 procedures during the study period, and 0.44
(p < 0.001) if the operator performed 30 or more proce-
dures. The kappa statistic for patients who had their
prostatectomy within the median value (84 days, 2.7 -
months) from the biopsy was 0.54 (p < 0.001), the sta-
tistic for the group who had a longer delay was 0.31
(p < 0.001).
In the univariate logistic regression analysis, the var-
iables associated with biopsy undergrading (cases = 95)
were age, sector of care of the first treatment, clinical
stage, number of biopsy cores, prostate volume, number
of procedures performed by the biopsy operator, and
the delay between the biopsy and the prostatectomy
(Table 1). In the multivariate analysis the variables inde-
pendently associated with undergrading selected for the
model were age, with a 4% increase by each extra year of
age (OR: 1.04, 95% CI: 1.00-1.09; p = 0.038), clinical stage
(OR: T3-T4 vs. T1-T2: 1.81, 95% CI: 1.06-3.10; p = 0.030),
number of cores (OR ≤9 cores vs. 10+: 1.93, 95% CI:
1.16-3.22; p = 0.011), and delay between biopsy and
prostatectomy, with 1% increase by each extra day of
delay between the 2 procedures (OR: 1.01, 95% CI:
1.00-1.01, p = 0.018) (Table 1).
Discussion
This study shows that in Geneva, the concordance be-
tween the GSs of biopsy and those of prostatectomy is
moderate, and lies within the current standards. Our
study also confirms that a lower number of biopsy cores
is an important and independent determinant of biopsy
undergrading.
The finding of a 67% exact match in grading between
biopsy and prostatectomy observed in Geneva is similar
to the proportion found in other studies. Muntener et al.
and Rajinikanth et al. both found exact match between
biopsy and prostatectomy GS categories as in 69% of
patients [4,8]. In particular the latter found that the
exact match improved from 58% in 1992–1996 to 75%
in 2002–2006, which represents a period closer to our
study period [8].
As reported by other authors, we found that a higher
number of biopsy cores is associated with a decreased
risk of undergrading [10,17]. In our study, the propor-
tion of exact matching improved significantly, from 62%
to 72%, when the patients had ten or more cores com-
pared with those who had nine or less, reinforcing the
2008 EAU guidelines recommendations of a minimum
of ten systematic cores per biopsy [12]. However, the
most recent EAU guidelines reduced to eight the mini-
mum number of biopsy cores recommended, suggesting
not to exceed twelve, with adaptations according to the
prostate volume [13], with the likely intent to keep a
high validity and at the same time reduce the patient’s dis-
comfort and the number of biopsy complications. Serious
complications may, in fact, occur after a prostate biopsy,
infection being one of the most serious ones [18].
As opposed to the report from Antunes et al. [10], we
found that the effect of the number of biopsy cores on
the risk of undergrading did not depend on the radical
prostatectomy specimen volume in multivariate analysis.
In our study, older age and a higher clinical stage of
the disease at diagnosis were also predictors of biopsy
undergrading, consistently with previous investigations
[9,11,17,19,20]. This could be linked to increasing intra-
tumoral heterogeneity of prostate cancer among men
with advanced age and advanced clinical stage, which
could affect clinical estimates of the grade of malig-
nancy [21-23].
We found that the concordance was much higher
among the group of patients with a shorter delay bet-
ween the biopsy and the prostatectomy (<= 84 days,
kappa = 0.54) than in the group with a delay longer than
84 days (kappa = 0.31). For this reason we adjusted our
multivariate model by the delay between the two proce-
dures. Consistently with our results, Kvale et al. found
that upgrading increased with increasing interval from
biopsy to radical prostatectomy [17]. Delay between bi-
opsy and surgery is more likely to have occurred in
lower grade tumors and may well explain the higher dis-
cordance with the final specimen. However, a histo-

























Figure 1 Concordance between biopsy and prostatectomy
individual Gleason scores. Empty circles represent concordant
scores between biopsy and prostatectomy; red filled circles
represent discordant scores. The size is proportional to the number
of cases falling in each combination.
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demonstrated by some authors, but its association with
disease progression is not clear [21-23].
This study has some limitations. Most importantly, both
biopsy and prostatectomy specimens were examined by
different laboratories, leading to possible inter-observer
variability common in GS interpretation, particularly for
less experienced pathologists [24]. In our study, however,
two main laboratories analyzed approximately 92% of all
prostate biopsies and approximately 70% of all prostate
surgical samples of prostate cancer cases, which suggests
a substantial experience by the examining laboratories, al-
though we cannot rule out variability between observers.
Furthermore, we found no significant difference of con-
cordance between biopsy and prostatectomy GS by the
average number of biopsy analyzed by each pathologist
(data not shown).
The strength of this study is its population-based ap-
proach and that it covers a recent period of time, i.e.
2004–2005. The period chosen overlaps with a refine-
ment of the Gleason grading system promoted in 2005
by the International Society of Urological Pathology con-
sensus conference (ISUP) [25]. However, we estimate
that this revision had a negligible impact on our results.
In fact, contrary to other studies which show after the
ISUP revision a tendency towards a higher Gleason prog-
nostic due mainly to an upgrading of the secondary pat-
tern, we did not observe any difference in the proportion
of high vs. low grade cancers by year of diagnosis [26-28].
Table 1 Determinants of Gleason score undergrading between biopsy and prostatectomy
Total Cases Controls Univariate OR1 (95% CI) p-value Multi-adjusted
OR1,2 (95% CI)
p-value
(n = 371) (n = 95) (n = 276)
Age at diagnosis years (in continuous ) 1.04 (1.00-1.08) 0.049 1.04 (1.00-1.09) 0.038
Socioeconomic status
High 128 31 97 1.00
Middle 155 43 112 1.20 (0.70-2.05) 0.502
Low 82 20 62 1.01 (0.53-1.93) 0.977
Unknown 6 1 5 0.63 (0.07-5.56) 0.674
Sector of care
Private 235 48 187 1.00
Public 136 47 89 2.06 (1.28-3.31) 0.003
PSA value
<10 242 63 179 1.00
10-20 39 14 25 1.59 (0.78-3.25) 0.203
>20 12 4 8 1.42 (0.41-4.88) 0.577
Unknown 78 14 64 0.62 (0.33-1.19) 0.149
Clinical stage
T1-T2 272 61 211 1.00 1.00
T3-T4 93 33 60 1.90 (1.14-3.17) 0.014 1.81 (1.06-3.10) 0.030
Tx 6 1 5 0.69 (0.08-6.03) 0.739 0.58 (0.06-5.37) 0.628
Number of biopsy cores
≤ 9 175 56 119 2.02 (1.24-3.28) 0.005 1.93 (1.16-3.22) 0.011
10 + 185 35 150 1.00 1.00
Unknown 11 4 7 2.45 (0.68-8.83) 0.171 2.65 (0.70-10.0) 0.151
Prostate volume cm3 (in continous) 0.99 (0.97-1.00) 0.031
Number of procedures performed by the
biopsy operator
1-29 110 37 73 1.75 (1.07-2.87) 0.026
30+ 254 57 197 1.00
Unknown 7 1 6 0.58 (0.07-4.88) 0.613
Delay between biopsy and prostatectomy
days (in continous)
1.01 (1.00-1.01) 0.004 1.01 (1.00-1.01) 0.018
1) OR: Odds Ratio derived from logistic regression considering as cases patients whose biopsy Gleason score was lower than the prostatectomy Gleason score and
as controls everybody else, 2) Simultaneously adjusted for age, pathological stage, number of biopsy cores and delay between the two procedures.
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Similarly, we did not detect a difference in neither the pri-
mary nor the secondary Gleason pattern, for both the bi-
opsy and the prostatectomy (p-value Pearson chi–square
pattern1 and pattern 2 biopsy: 0.856 and 0.663; pattern1
and pattern2 prostatectomy: 0.983 and 0.679, respec-
tively). Biopsy GS is an important outcome predictor of
prostate cancer, and especially so for patients treated con-
servatively. Of particular clinical relevance is the biopsy
undergrading of patients from grade seven or more to
grade six or less, as these patients would move from a
high/intermediate to a low risk group with a high prob-
ability of receiving a less aggressive treatment approach.
In our study, there were 147 patients with T1-T2 prostate
cancer stage, PSA < 10 ng/ml, and a biopsy Gleason
grade <7 who would have been ideal candidates for
active surveillance. After the prostatectomy the Gleason
was upgraded to a grade > =7 for 36 of these patients.
Thus, in this population-based sample approximately 10%
of patients with high-risk disease would have been
undertreated. These results support the active surveillance
protocols to rebiopsy patients one year after their diagno-
sis to reduce the proportions of understaged patients to
approximately 5% [29].
Conclusions
In conclusion, this study confirms that number of biopsy
cores impacts the concordance between Gleason of bi-
opsy and prostatectomy. Several actions can be taken to
optimize concordance of prostate cancer grading bet-
ween needle biopsy and the prostatectomy specimen.
Most importantly, adequate training of urologists in
performing biopsies has the potential not only to op-
timize diagnostic accuracy but to minimize the patient’s
discomfort and morbidity as well. Extended needle bi-
opsy protocols, with at least ten cores, improve cancer
detection rates and the concordance of biopsy results
with the prostatectomy findings. All pathologists evalu-
ating prostate tissues should be systematically trained in
Gleason grading. Furthermore, as recently recommended
by the National Institute for Health and Clinical Ex-
cellence guidelines [1], results of all prostate biopsies
should be reviewed by a urological cancer multidisciplin-
ary team. Men who have selected active surveillance as
treatment option should have a repeat biopsy after a re-
view by this team of the risk characteristics, including
life expectancy, PSA level, digital rectal examination, and
prostate volume. Use of modern imaging devices, such
as three dimensional ultrasound during needle biopsy,
could further help to improve diagnostic accuracy prior
to clinical decision making.
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